OncoMatch/Clinical Trials/NCT06013618
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Is NCT06013618 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for neuroblastoma.
Treatment: Naxitamab monotherapy · GM-CSF · Irinotecan · Temozolomide · Naxitamab in combination therapy · GM-CSF with combination regimen · Sintilimab — This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in Sun Yat-sen University Cancer Center.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Neuroblastoma
Demographics
Prior therapy
Cannot have received: investigational drug
has received another investigational drug within the 4 weeks prior to commencing treatment with naxitamab
Lab requirements
Cardiac function
Left ventricular ejection fraction of <50% by echocardiography OR other clinically relevant cardiac disorders at the discretion of the investigator
Left ventricular ejection fraction of <50% by echocardiography OR other clinically relevant cardiac disorders at the discretion of the investigator
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06013618 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages